Efficacy of terazosin for overactive bladder symptoms and sexual function in patients withoveractive bladder and symptomatic benign prostatic hyperplasia: a prospectivemulticenter trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study is to evaluate the efficacy of terazosin in the treatment of overactive bladder (OAB) symptoms and sexual dysfunction in patients with symptomatic benign prostatic hyperplasia (BPH) and OAB. Methods: Of 200 men aged 50-80 years with symptomatic BPH, an International Prostatic Symptom Score (IPSS) ≥8 accompanied by OAB symptoms, 185 patients completed treatment with terazosin 2-5 mg once daily for 8 weeks. Patients were asked to complete a voiding diary, the International Index of Erectile Function (IIEF) questionnaire, and the IPSS at baseline, 4 and 8 weeks. Results: 8-week terazosin treatment improved OAB symptoms as well as reducing IPSS (19.8 to 12.7) and IIEF (34.4 to 37.4) scores. OAB symptoms improved significantly, irrespective of symptom severity by the IPSS, but the IIEF score only increased in patients with severe symptoms. Conclusions: Additional studies are needed to further evaluate the placebo effect. However, terazosin monotherapy is effective in patients with symptomatic BPH and OAB, and may increase sexual function in patients with severely symptomatic BPH. (J Korean Continence Soc 2008;12:36-41)
Abstract
Objective: This study is to evaluate the efficacy of terazosin in the treatment of overactive bladder (OAB) symptoms and sexual dysfunction in patients with symptomatic benign prostatic hyperplasia (BPH) and OAB. Methods: Of 200 men aged 50-80 years with symptomatic BPH, an International Prostatic Symptom Score (IPSS) ≥8 accompanied by OAB symptoms, 185 patients completed treatment with terazosin 2-5 mg once daily for 8 weeks. Patients were asked to complete a voiding diary, the International Index of Erectile Function (IIEF) questionnaire, and the IPSS at baseline, 4 and 8 weeks. Results: 8-week terazosin treatment improved OAB symptoms as well as reducing IPSS (19.8 to 12.7) and IIEF (34.4 to 37.4) scores. OAB symptoms improved significantly, irrespective of symptom severity by the IPSS, but the IIEF score only increased in patients with severe symptoms. Conclusions: Additional studies are needed to further evaluate the placebo effect. However, terazosin monotherapy is effective in patients with symptomatic BPH and OAB, and may increase sexual function in patients with severely symptomatic BPH. (J Korean Continence Soc 2008;12:36-41)
참고문헌 (20)
- Burnett AL, "Benign prostatic hyperplasia in primary care: what you need to know", J Urol, 175, pp.S19~24 (2006)
- Peters TJ., "The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms", J Urol, 157, pp.885~9 (1997)
- Abrams P, "Wein A;Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub=committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~78 (2002)
- Price D., "Potential mechanisms of action of superselectivealpha(1)-adrenoceptor antagonists", Eur Urol, 40(4), pp.5~11 (2001)
- van Moorselaar RJ., "Vallancien G; ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction", BJU Int, 95, pp.603~608 (2005)
- Kirby RS., "Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction", BJU Int, 95, pp.103~109 (2005)
- Freeman R, "Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine", Obstet Gynecol, 102, pp.605~11 (2003)
- Kuo HC., "Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxina for idiopathic detrusor overactivity", J Urol, 178, pp.1359~63 (2007)
- Price DT., "Identification, quantification, andlocalization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate", J Urol, 150, pp.546~51 (1993)
- Malloy BJ., "Donatucci CF, Schwinn DA. Alpha1-adrenergic receptor subtypes in human detrusor", J Urol, 160, pp.937~4 (1998)
- Yokoyama O., "Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats", Neurourol Urodyn, 25, pp.461~7 (2006)
- Reynard JM., "Does anticholinergic medication have arole for men with lower urinary tract symptoms", benign prostatic hyperplasia either alone or in combination with other agents?, 2004, pp.14, 13~6
- Reilly CM, "Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum", J Androl, 18, pp.26~31 (1997)
- Traish AM., "Identification of alpha 1-adrenergic receptor subtypes in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells", Receptor, 5, pp.145~-57 (1995)
- Vallancien G., "Alf-One Study Group: Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms", J Urol, 169, pp.2257~61 (2003)
- Rosen RC., "Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)", Eur Urol, 47, pp.824~37 (2005)
- De Rose AF., "Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia", Urol Int, 68, pp.95~8 (2002)
- Tanaka Y., "Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia", J Urol, 167, pp.2492~5 (2002)
- Lee E., "Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses", Br J Urol, 80, pp.606~11 (1997)
- van Leeuwen JH., "The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms", Eur Urol, 50, pp.440~52 (2006)